We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+10.12%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$2.03B
AUM Growth
+$258M
Cap. Flow
+$193M
Cap. Flow %
9.48%
Top 10 Hldgs %
34.65%
Holding
2,402
New
679
Increased
420
Reduced
419
Closed
794

Sector Composition

Rank Sector Weight
1 Healthcare 7.64%
2 Technology 6.61%
3 Industrials 5.39%
4 Communication Services 5.27%
5 Consumer Discretionary 4.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BCRX icon
1326
BioCryst Pharmaceuticals
BCRX
$2.38B
$14K ﹤0.01%
+3,587
New +$21.6K
PRTA icon
1327
Prothena Corp
PRTA
$449M
$14K ﹤0.01%
+1,355
New +$13.9K
TT icon
1328
Trane Technologies
TT
$105B
$14K ﹤0.01%
+114
New +$13.6K
TMX
1329
DELISTED
Terminix Global Holdings, Inc.
TMX
$14K ﹤0.01%
+265
New +$13.6K
MIME
1330
DELISTED
Mimecast Limited
MIME
$14K ﹤0.01%
300
-786
-72% -$37.4K
GSUM
1331
DELISTED
Gridsum Holding Inc.
GSUM
$14K ﹤0.01%
4,890
BWB icon
1332
Bridgewater Bancshares
BWB
$592M
$13K ﹤0.01%
+1,136
New +$12.4K
ELF icon
1333
e.l.f. Beauty
ELF
$5.44B
$13K ﹤0.01%
+957
New +$11.6K
FTV icon
1334
Fortive
FTV
$18.4B
$13K ﹤0.01%
249
-1,373
-85% -$71.3K
IDXX icon
1335
Idexx Laboratories
IDXX
$46.5B
$13K ﹤0.01%
49
-88
-64% -$21.7K
NFE icon
1336
New Fortress Energy
NFE
$98M
$13K ﹤0.01%
+1,096
New +$12.6K
TREE icon
1337
LendingTree
TREE
$447M
$13K ﹤0.01%
+32
New +$12.2K
VNDA icon
1338
Vanda Pharmaceuticals
VNDA
$309M
$13K ﹤0.01%
946
-788
-45% -$12.5K
WYNN icon
1339
Wynn Resorts
WYNN
$10.5B
$13K ﹤0.01%
108
-3,791
-97% -$487K
XME icon
1340
State Street SPDR S&P Metals & Mining ETF
XME
$4.22B
$13K ﹤0.01%
+472
New +$13.1K
SCWX
1341
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
$13K ﹤0.01%
+1,000
New +$16.6K
GBL
1342
DELISTED
GAMCO Investors, Inc.
GBL
$13K ﹤0.01%
669
VWTR
1343
CALL
DELISTED
Vidler Water Resouces, Inc. Common Stock
VWTR
$13K ﹤0.01%
1,100
-6,000
-85% -$66.4K
SRGA
1344
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$13K ﹤0.01%
+99
New +$14.3K
OXFD
1345
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$13K ﹤0.01%
923
-30,263
-97% -$463K
DPLO
1346
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$13K ﹤0.01%
+2,066
New +$11K
LKSD
1347
DELISTED
LSC Communications, Inc.
LKSD
$13K ﹤0.01%
+3,500
New +$20.6K
OLBK
1348
DELISTED
Old Line Bancshares, Inc.
OLBK
$13K ﹤0.01%
+505
New +$12.9K
AMC icon
1349
CALL
AMC Entertainment Holdings
AMC
$2.29B
$12K ﹤0.01%
130
-40
-24% -$5.33K
ASMB icon
1350
Assembly Biosciences
ASMB
$524M
$12K ﹤0.01%
+75
New +$14.3K

Similar funds

Prelude Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Prelude Capital Management held 2,402 positions worth $2.03B, up 15% from $1.77B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Prelude Capital Management deployed $193M of net new capital in Q2 2019, opening 679 new positions and adding to 420 existing holdings. Its largest new stake was Anadarko Petroleum: 593,600 shares worth $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 7.6% of assets, up from 6.7% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Red Hat Inc, an estimated $8.6M trimmed.

  • Prelude Capital Management's largest Q2 2019 buy was Anadarko Petroleum: 593,600 shares worth $41.9M.
  • Prelude Capital Management added most to Allergan plc in Q2 2019, an estimated $27.2M increase.
  • Prelude Capital Management's biggest Q2 2019 reduction was Red Hat Inc, cutting an estimated $8.6M.
  • Prelude Capital Management fully exited Travelport Worldwide Limited in Q2 2019, selling an estimated $27.8M.
  • Prelude Capital Management's ten largest holdings make up 35% of its $2.03B portfolio in Q2 2019.
  • Prelude Capital Management opened 679 new positions and closed 794 in Q2 2019.
  • Prelude Capital Management's portfolio value rose 15% quarter-over-quarter to $2.03B.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.